Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETAMINOPHEN AND CODEINE PHOSPHATE vs MEVACOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.
Mild to moderate pain,Pain accompanied by fever
Primary hypercholesterolemia,Mixed dyslipidemia,Homozygous familial hypercholesterolemia,Prevention of coronary heart disease,Slow progression of coronary atherosclerosis
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
10-80 mg orally once daily in the evening.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
The terminal elimination half-life of lovastatin is approximately 1-2 hours for the parent drug. However, the active metabolite (lovastatin acid) has a half-life of about 1.7-2.6 hours. Despite the short half-life, the duration of HMG-Co A reductase inhibition is prolonged due to enterohepatic recirculation and tissue distribution. Once-daily dosing is effective for LDL-C reduction.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Primarily hepatic via CYP3A4 isoenzyme; significant first-pass metabolism.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Lovastatin is primarily excreted via the biliary/fecal route (approximately 80-85% of the absorbed dose) as metabolites. Renal excretion accounts for about 10% of the administered dose, mostly as metabolites; less than 5% is excreted unchanged in urine.
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Lovastatin and its active metabolite are extensively bound to plasma proteins, with binding >95% for the parent drug and >92% for lovastatin acid. The primary binding protein is albumin.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
The apparent volume of distribution (Vd) for lovastatin is approximately 0.3-0.6 L/kg, indicating distribution into tissues, but predominantly into the liver (the primary site of action). High Vd reflects extensive tissue binding.
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Oral bioavailability of lovastatin is low, approximately 5% for the parent drug due to extensive first-pass metabolism in the liver. The active metabolite (lovastatin acid) is formed via hydrolytic metabolism. Food increases absorption, so it is recommended to be taken with the evening meal.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
No dose adjustment required for GFR >30 m L/min; if GFR <30 m L/min, start at 5 mg/day and increase cautiously.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Contraindicated in active liver disease or unexplained transaminase elevations; Child-Pugh Class A/B: use with caution, no specific dose adjustment; Child-Pugh Class C: contraindicated.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
For heterozygous familial hypercholesterolemia: 10-20 mg orally once daily in the evening for ages 10-17; adjust based on response.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Start at lower end of dosing range (10 mg/day) due to increased risk of myopathy; titrate cautiously.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
No FDA black box warning.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Myopathy/rhabdomyolysis risk increased with high doses or concomitant use of CYP3A4 inhibitors,Hepatic enzyme elevations; monitor liver function tests,Avoid use in patients with active liver disease or unexplained persistent transaminase elevations,Use caution in patients with predisposing factors for renal failure
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Active liver disease,Unexplained persistent elevations of serum transaminases,Hypersensitivity to any component of the product,Pregnancy,Lactation
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
Grapefruit juice inhibits CYP3A4 and increases lovastatin levels, increasing risk of myopathy/rhabdomyolysis; avoid concurrent intake. High-fat meals enhance absorption; take with evening meal to optimize efficacy.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Pregnancy Category X. Contraindicated in all trimesters due to risk of fetal skeletal muscle damage, CNS abnormalities, and cardiac defects. Case reports of limb defects, cleft palate, and fetal death.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Contraindicated. Excreted into human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including interference with cholesterol biosynthesis.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Not applicable; contraindicated in pregnancy. No dose adjustments recommended as drug should be discontinued prior to conception or immediately upon pregnancy detection.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
MEVACOR (lovastatin) is a prodrug that requires CYP3A4 metabolism; avoid coadministration with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, protease inhibitors, nefazodone, grapefruit juice). Titrate dose based on LDL-C response; start at 20 mg daily with evening meal. Monitor liver function tests at initiation and as clinically indicated; contraindicated in active liver disease or unexplained transaminase elevations. Increased risk of myopathy/rhabdomyolysis with concurrent fibrates (especially gemfibrozil), niacin (>1 g/day), and CYP3A4 inhibitors. Use cautiously in patients with renal impairment.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
Take this medication with the evening meal to enhance absorption and reduce side effects.,Avoid consuming grapefruit or grapefruit juice while taking this drug, as it can increase the risk of side effects.,Report unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.,Do not take over-the-counter niacin or other cholesterol-lowering medications without consulting your healthcare provider.,Inform your doctor about all other medications, including herbal supplements and over-the-counter drugs.,Adhere to a heart-healthy diet and exercise regimen as prescribed by your healthcare provider.,Adverse effects may include headache, abdominal pain, and nausea; contact your doctor if severe or persistent.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETAMINOPHEN AND CODEINE PHOSPHATE vs MEVACOR, answered by our medical review team.
ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. MEVACOR is a HMG-CoA Reductase Inhibitor (Statin) that works by Competitive inhibitor of HMG-Co A reductase, the rate-limiting enzyme in cholesterol biosynthesis. Reduces hepatic cholesterol synthesis, leading to increased LDL receptor expression and enhanced clearance of LDL from plasma.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETAMINOPHEN AND CODEINE PHOSPHATE and MEVACOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. The standard adult dose of MEVACOR is: 10-80 mg orally once daily in the evening.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETAMINOPHEN AND CODEINE PHOSPHATE and MEVACOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. MEVACOR is classified as Category C. Pregnancy Category X. Contraindicated in all trimesters due to risk of fetal skeletal muscle damage, CNS abnormalities, and cardiac defects. Case reports of limb defects, cleft pal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.